Novartis’s big new drug hope Entresto has been recommended for use in some patients with heart failure by Britain’s cost agency NICE, which said on Friday it believed the treatment […]
More than half of the world’s population will live in countries where medicine use will exceed one dose per person per day by 2020, up from 31 percent in 2005, as the “medicine use gap” between developed and pharmerging markets narrows, according to research by the IMS Institute for Healthcare Informatics.
A pediatric doctor in Alabama had to scramble to find a less expensive supply of a lifesaving drug to treat an infant who was suffering from a parasitic infection. […]
European and U.S. drug regulators are looking into whether a defective blood clotting test device affected a trial involving Bayer’s top-selling anti-clotting drug Xarelto, hitting the German drugmaker’s shares. The […]
Israel’s Teva Pharmaceutical Industries said the U.S. Food and Drug Administration approved an injectable and infusion version of its cancer drug bendamustine. The drug, sold under the brand name Bendeka, […]
Tonix Pharmaceuticals Holding Corp said it was teaming up with the U.S. Department of Defense to further develop its experimental PTSD drug, which if approved, could be the first treatment […]
THOUSAND OAKS, Calif. and KENILWORTH, N.J., Dec. 4, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced a cancer […]
NEW YORK – Turing Pharmaceuticals’ Martin Shkreli, once dubbed the most hated man in America, might not have a difficult time holding onto that title after telling a healthcare panel […]
PHOENIX – After its stock dropped nearly 20 percent, Insys Therapeutics defended its practices from allegations it falsified data in order to sell more of its painkiller, the fentanyl-based Subsys. […]
Researchers at Brigham and Women’s Hospital have discovered even more promising data around a Novartis drug for heart failure, saying that the drug increased life expectancy by nearly two years. […]
